GeneDx (NASDAQ:WGS – Get Rating) and DCC (OTCMKTS:DCCPF – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.
Volatility & Risk
GeneDx has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, DCC has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for GeneDx and DCC, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeneDx | 0 | 0 | 0 | 0 | N/A |
| DCC | 0 | 0 | 1 | 0 | 3.00 |
Earnings & Valuation
This table compares GeneDx and DCC’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GeneDx | $212.20 million | 0.80 | -$245.39 million | ($0.93) | -0.47 |
| DCC | $24.23 billion | 0.23 | $426.64 million | N/A | N/A |
DCC has higher revenue and earnings than GeneDx.
Institutional and Insider Ownership
56.0% of GeneDx shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares GeneDx and DCC’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeneDx | -121.31% | -53.31% | -36.04% |
| DCC | N/A | N/A | N/A |
Summary
DCC beats GeneDx on 6 of the 9 factors compared between the two stocks.
About GeneDx
Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn.
About DCC
DCC Plc engages in the provision of international sales, marketing, and business support services. It operates through the following segments: DCC Energy, DCC Healthcare, and DCC Technology. The DCC Energy segment includes the sales and marketing of liquefied petroleum gas, and offers transport and heating energy, lower emission fuels and biofuels, and related services to consumers and businesses across Europe. The DCC Healthcare segment provides products and services to healthcare providers and health and beauty brand owners. The DCC Technology segment serves as a route-to-market and supply chain partner for global technology brands. The company was founded by Jim Flavin in 1976 and is headquartered in Dublin, Ireland.
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
